Inhibition of cytochromes P450: Existing and new promising therapeutic targets

Drug Metabolism Reviews

Volumn 39, Issue 2-3, 2007, Pages 481-499

  Schuster, Inge ^a   Bernhardt, Rita ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Drug target; P450; P450 inhibition

Indexed keywords

ALDOSTERONE SYNTHASE; ANASTROZOLE; AROMATASE; CYTOCHROME P450; CYTOCHROME P450 17; CYTOCHROME P450 4A; CYTOCHROME P450 INHIBITOR; EXEMESTANE; FLUCONAZOLE; GLUTETHIMIDE; HESPERETIN; ITRACONAZOLE; KETOCONAZOLE; LETROZOLE; LIAROZOLE; MITOTANE; OZAGREL; RIDOGREL; STEROL 14ALPHA DEMETHYLASE; TESTOLACTONE; VORICONAZOLE;

ASTHMA; BREAST CANCER; CANCER; CUSHING SYNDROME; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HYPERPARATHYROIDISM; ICHTHYOSIS; INFECTION; METABOLIC DISORDER; MYCOSIS; NONHUMAN; OXIDATION; PROSTATE CANCER; PSORIASIS; REVIEW;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; ISOENZYMES;

EID: 34548394436     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602530701498455     Document Type: Review

References (97)

1. Anderson, J. L., Chapman, S. K. (2005). Ligand probes for heme proteins. Dalton Trans: 13-24.
2. Angelastro, M. R., Laughlin, M. E., Schatzman, G. L., Bey, P., Blohm, T. R. (1989). 17,-(Cyclopropylamino)-Androst-5-en-3,-ol, a Selective Mechanism-Based Inhibitor of Cytochrome P45017alpha (Steroid 17alpha-hydroxylase/C17, 20Lyase). Biochem. Biophys. Res. Commun. 162:1571-1577.
3. Attard, G., Sarker, D., Reid, A., Molife, R., Parker, C., de Bono, J. S. (2006). Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. British Journal of Cancer 95:767-774.
4. Ayub, M., Level, M. (1987). Inhibition of Testicular 17α- hydroxylase and 17, 20-Lyase but not 3-Hydroxysteroid Dehydrogenase-Isomerase or 17-Hydroxysteroid Oxidoreductase by Ketoconazole and Other Imidazole drugs. J. Steroid Biochem. 28:521-531.
5. Barrie, S. E., Rowlands, M. G., Foster, A. B., Jarman, M. (1989). Inhibition of 17α-hydroxylase/ C17, 20Lyase by bifluranol and its analogues. J. Steroid Biochem. 33:1191-1195.
6. Barrie, S. E., Potter, G. A., Goddard, P. M., Haynes, B. P., Dowsett, M., Jarman, M. (1994). Pharmacology of Novel Steroidal Inhibitors of Cytochrome P45017alpha (17alpha-Hydroxylase/ C17, 20 Lyase. J. Steroid Biochem. Mol. Biol. 50:267-273.
7. Belkina, N. V., Lisurek, M., Ivanov, A. S., Bernhardt, R. (2001). Modelling of three-dimensional structures of cytochromes P450 11B1 and 11B2. J. Inorg. Biochem. 87:197-207.
8. Boelsterli, U. A. (2003). Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 192:307-322.
9. Böttner, B., Bernhardt, R. (1996a). Changed ratios of glucocorticoids/mineralocorticoids caused by point mutations in the putative I-helix regions of CYP11B1 and CYP11B2. Endocr. Res. 4:455-461.
10. Böttner, B., Schrauber, H., Bernhardt, R. (1996b). Engineering a mineralocorticoid- to a glucocorticoid-synthesizing cytochrome P450. J. Biol. Chem. 271:8028-8033.
11. Böttner, B., Denner, K., Bernhardt, R. (1998). Conferring novel aldosterone synthesis to human CYP11B1 by replacing key amino acid residues for CYP11B2 specific ones. Eur. J. Biochem. 252:458-466.
12. Bonkovsky, H. L. (2007). AASLD-FDA-NiH-PhRMA Hepatotoxicity Meeting www.fda.gov/cder/livertox/presentations2007.htm
13. Bostwick, D. G., Cooner, W. H., Denis, L., Jones, G. W., Scardino, P. W., Murphy, G. P. (1992). The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 70:291-301.
14. Brilla, C. G. (2000). Aldosterone and moyocardial fibrosis in heart failure. Herz 25:299-306.
15. Brown, A. J., Ritter, C., Slatopolsky, E. (1999). Vitamin D. Am. J. Physiol. 277:157-175.
16. Brueggemeier, R. W., Hackett, J. C., Diaz-Cruz, E. S. (2005). Aromatase inhibitors in the treatment of breast cancer. Endocrine Reviews 26:331-345.
17. Bureik, M., Hübel, K., Dragan, C.-A., Scher, J., Becker, H., Lenz, N., Bernhardt, R. (2004). Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. Molecular and Cellular Endocrinology 217:249-254.
18. Cai, W., Counsell, R. E., Schteingart, D. E., Sinsheimer, J. E., Vaz, A. D. N., Wotring, L. L. (1997). Adrenal proteins bound by a reactive intermediate of mitotane. Cancer Chemother. Pharmacol. 39:537-540.
19. Chen, P., Guo, M., Wygle, D., Edwards, P. A., Falck, J. R., Roman, R. J., Scicli, A. G. (2005). Inhibitors of Cytochrome P450 4A Suppress Angiogenic Responses. Amer. J. Pathol. 166:615-624.
20. De Coster, R., Wouters, W., Bruynseels, J. (1996). P-450 dependent enzymes as targets for prostate cancer therapy, J. Steroid Biochem. Mol. Biol. 56:133-143.
21. Delyani, J. A. (2000). Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 57:1408-1411.
22. Denner, K., Doehmer, J., Bernhardt, R. (1995a). Cloning of CYP11B1 and CYP11B2 from normal human adrenals and their functional expression in COS- and V79 Chinese Hamster cells. Endocr. Res. 21:443-448.
23. Denner, K., Vogel, R., Schmalix, W., Doehmer, J., Bernhardt, R. (1995b). Cloning and stable expression of the human mitochondrial cytochrome P45011B1 cDNA in V79 chinese hamster cells and their application for testing of potential inhibitors." Pharmacogenetics 5:89-96.
24. Denner, K., Bernhardt, R. (1998). Inhibition studies of steroid conversions mediated by human CYP11B1 and CYP11B2 expressed in cell cultures. In: Oxygen Homeostasis and its Dynamics. Tokyo, Berlin, Heidelberg, New York, Springer-Verlag, pp. 231-236.
25. Dogne, J. M., de Leval, X., Benoit, P., Rolin, S., Pirotte, B., Masereel, B. (2002). Therapeutic potential of thromboxane inhibitors in asthma. Expert. Opin. Investig. Drugs 11:275-281.
26. De With, K., Steib-Bauert, M., Knoth, H., Dörje, F., Strehl, E., Rothe, U., Maier, L., Kern, W. V. (2005). Hospital use of systemic antifungal drugs. BMC Clin. Pharmacol. 5:1 http://www.biomedcentral.com/1472-6904/5/ 1.
27. Ehmer, P. B., Bureik, M., Bernhardt, R., Muller, U., Hartmann, R. W. (2002). Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells. J. Steroid Biochem. Mol. Biol. 81:173-179.
28. Ekins, S., Mankowski, D. C., Hoover, D. J., Lawton, M. P., Treadway, J. L., Harwood, H. J. (2007). Three Dimensional-Quantitative Structure Activity Relationship Analysis of Human CYP51 Inhibitors. Drug. Metab. Dispos. 35:493-500.
29. Ekroos, M., Sjögren, T. (2006). Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. U.S.A. 103:13682-13687.
30. Guengerich, F. P., Wu, Z. L., Bartelson, C. J. (2005). Function of human cytochrome P450s: characterization of the orphans. Biochem. Biophys. Res. Commun. 338:465-469.
31. Hakki, T., Bernhardt, R. (2006). CYP 17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacology & Therapeutics 111:27-52.
32. Hartmann, R. W., Ehmer, P. B., Haidar, S., Hector, M., Jose, J., Klein, C. D. P., Seidel, S. B., Sergejew, T. F., Wachall, B. G., Wächter, G. A., Zhuang, Y. (2002). Inhibition of CYP17, a new strategy of the Treatment of prostate cancer. Arch. Pharm. Med. Chem. 4:119-128.
33. Howell, A., Howell S. J., Clarke, R., Anderson E. (2001). Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (ALs) now fit into breast cancer treatment algorithms? J. Steroid Biochem. Mol. Biol. 79:227-237.
34. Jarman, M., Barrie, S. E., Deadman, J. J., Houghton, J., McCague, R. (1990). Hydroxyperfluoroazobenzenes: Novel Inhibitors of Enzymes of Androgen Biosynthesis. J. Med. Chem. 33:2452-2455.
35. Jonat, W., Mundhenke, C. (2007a). The FACE Trial: Letrozole or Anastrozole as Initial Adjuvant Therapy? Cancer Invest. 25:14-18.
36. Jonat, W., Hilpert, F., Kaufmann, M. (2007b). Aromatase inhibitors: a safety comparison. Expert Opinion on Drug Safety 6:165-174.
37. Kahraman, M., Sinishtaj, S., Dolan, P. M., Kensler, T. W., Peleg, S., Saha, U., Chuang, S. S., Bernstein, G., Korczak, B., Posner, G. H. (2004). Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1 alpha,25-dihydroxyvitamin D(3). J. Med. Chem. 47:6854-6863.
38. Karlgren, M., Ingelman-Sundberg, M. (2007) Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy. Expert Opin. Ther. Targets 11:61-67.
39. Kent, U. M., Jushchyshyn M. I., Hollenberg, P. W. (2001). Mechanism-Based Inactivators as Probes of Cytochrome P450 Structure and Function. Curr. Drug Metab. 2:215-243.
40. Lam, R. (2004). High Dose Ketoconazole Plus Hydrocortisone (HDK+ HC). PCRI Insights Newsletter 7(2) (http://www.prostate-cancer.org/education/ andeprv/Lam_HDK.html)
41. Lepesheva, G. I., Waterman, M. R. (2007). Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim. Biophys. Acta 1770:467-477.
42. Lijnen, P., Petrov, V. (2000). Induction of cardiac fibrosis by aldosterone. J. Mol. Cell. Cardiac. 32:865-879.
43. Ljubimov, A. V., Grant, M. B. (2005). P450 in the angiogenesis affair. Am. J. Pathol. 166:341-344.
44. Long, B., Grigoryev, D. N., Nnane, I. P., Liu, Y., Ling, Y. Z., Brodie, A. M. (2000). Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res. 60:6630-6640.
45. MacFadyen, R. J., Barr, C. S., Struthers, A. D. (1997). Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc. Res. 35:30-34.
46. Mantero, F., Lucarelli, G. (2000). Aldosterone antagonism in hypertension and heart failure. Ann. Endocrinol. 61:52-60.
47. McCague, R., Rowlands, M. G., Barrie, S. E., Houghton, J. (1990). Inhibition of Enzymes of Estrogen and Androgen Biosynthesis by Ester of 4-Pyridylacetic acid. J. Med. Chem. 33:3050-3055.
48. McFadyen M. C. E., Murray, G. I. (2005). Cytochrome P450 1B1: a novel anticancer therapeutic target. Future Oncol. 1:259-263.
49. McGurie, W. L. (1980). Steroid hormone receptors in breast cancer treatment strategy. Recent Prog. Horm. Res. 36:135-156.
50. Miller W. H. (1998). The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 83:1471-1482.
51. Murray, M. (2004). Review of: Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Breast Cancer Online (www.bco.org): 7(10).
52. Nagpal, S., Na, S., Rathnachalam, R. (2005). Noncalcemic Actions of Vitamin D Receptor Ligands. Endocrine Reviews 26:662-687.
53. Nakajin, S., Takahashi, K., Shinoda, M. (1988). Inhibitory Effect and Spectral Changes on Pig Testicular Cytochrome P-450 (17αhydroxylase/C17, 20-lyase) by 20,-Hydroxy-C21-steroids. Yakugaku Zasshi 108:1188-1195.
54. Nakajin, S., Takahashi, K., Shinoda, M. (1989). Inhibitory effect and Interaction of Stanozolol with Pig Testicular Cytochrome P-450 (17α-hydroxylase/C17, 20-Lyase). Chem. Pharm. Bull. (Tokyo) 37:1855-1858.
55. Njar V. C. O. (2002). Cytochrome P450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. Mini Rev. Med. Chem 2:261-269.
56. Obermayer-Straub, P., Strassburg, C. P., Manns, M. P. (2000). Target proteins in human autoimmunity: cytochromes P450 and UDP-glucuronyltransferases. Can. J. Gastroenterol. 14:429-439.
57. O'Donnell, A., Judson, I., Dowsett, M., Raynaud, F., Dearnaley, D., Mason, M., Harland, S., Robbins, A., Halbert, G., Nutley, B., Jarman, M. (2004). Hormonal impact of the 17alpha-hydroxylase/ C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 90:2317-2325.
58. Overington, J. P., Al-Lazikani, B., Hopkins, A. L. (2006) How many drug targets are there? Nature Reviews Drug Discovery 5:993-996.
59. Pasqualini, J. R., Chetrite, G., Blacker, C., Feinstein M. C., Delalonde, L., Talbi, M. Maloche, C. (1996). Concentration of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 81:1460-1464.
60. Patel, J., Khandelwal, A., Chopra, P., Handratta, V., Njar, V. (2007). Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents. Cancer Chemother. Pharmacol. Mar 8: (Epub ahead of print).
61. Patscheke, H. (1990). Current concepts for a drug-induced inhibition of formation and action of thromboxane A2. Blut 60:261-268.
62. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Peerez, A., Palensky, J., Wittes, J. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldosterone Evaluation study Investigators. N. Engl. J. Med. 341:709-717.
63. Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., Neaton, J., Roniker, B., Hurley, S., Burns, D., Bittman, R., Kleiman, J. (2001). The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc. Drugs Ther. 1:79-87.
64. Pitt, B. (2002). Do diuretics and aldosterone receptor antagonists improve ventricular remodeling? J. Card. Fail. 8:491-493.
65. Podust, L. M., Stojan, J., Poulos, T. L., Waterman, M. R. (2001). Substrate recognition sites in 14alpha-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51. J. Inorg. Biochem. 87:227-235.
66. Posner, G. H., Crawford, K. R., Yang, H. W., Kahraman, M., Jeon, H. B., Li, H., Lee, J. K., Suh, B. C., Hatcher, M. A., Labonte, T., Usera, A., Dolan, P. M., Kensler, T. W.. Peleg, S., Jones, G., Zhang, A., Korczak, B., Saha, U., Chuang, S. S. (2004). Potent, low-calcemic, selective inhibitors of CYP24 hydroxylase: 24-sulfone analogs of the hormone 1α,25-dihydroxyvitamin D3. J. Steroid Biochem. Mol. Biol. 89-90:5-12.
67. Potter, G. A., Barrie, S. E., Jarman, M., Rowlands, M. (1996). Novel Steroidal Inhibitors of Human Cytochrome P45017alpha (17α-Hydroxylase/C17- 20 Lyase): Potential Agents for the Treatment of Prostatic Cancer. J. Med. Chem. 38:2463-2471.
68. Ramires, F. J., Sun, Y., Weber, K. T. (1998). Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J. Mol. Cell. Cardiol. 30:475-483.
69. Rodriguez-Antona C., Ingelman-Sundberg, M. (2006). Cytochrome P450 pharmacogenetics and cancer. Oncogene 25:1679-1691.
70. Roos T. C., Jugert, F. K., Merk, H. F., Bickers, D. R. (1998). Retinoid metabolism in the skin. Pharmacol. Rev 50:315-333.
71. Rowlands, M. G., Barrie, S. E., Chan, F., Houghton, J., Jarman, M., McCague, R., Potter, G. A. (1995). Esters of 3-Pyridylacetic Acid that Combine Potent Inhibition of 17α-Hydroxylase/ C17,20-Lyase (Cytochrome P45017R) with Resistance to Esterase hydrolysis. J. Med. Chem. 38:4191-4197.
72. Russ, A. P., Lampel, S. (2005). The druggable genome: an update. DDT 10:1607-1610.
73. Santen, R. J., Samojlik, E., Lipton, A., Harvey, H., Ruby, E. R., Wells, S. A., Kendall, J. (1977). Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer. 39:2948-2958.
74. Schuster, I. (1993). Ergosterol Synthesis: The major Target in Antimycotic Therapy. In: Ruckpaul, K., Rein, R. ed Frontiers in Biotransformation, Vol. 8, Berlin: Akademie Verlag, pp. 147-185.
75. Schuster, I. (1985). The interaction of representative members from two classes of antimycotics - the azoles and the allylamines - with cytochromes P-450 in steroidogenic tissues and liver. Xenobiotica 15:529-546.
76. Schuster, I., Egger, H., Bikle, D., Herzig, G., Reddy, G. S., Stuetz, A., Stuetz, P., Vorisek, G. (2001). Selective inhibition of vitamin D hydroxylases. Steroids 66:409-422.
77. Schuster, I., Astecker, N., Egger, H., Herzig, G., Reddy, G. S., Schuessler, M., Vorisek, G., Wachter, C. (2006). Inhibitors of vitamin D-hydroxylases: mechanistic tools and therapeutic aspects. In: Stolzt VD ed. New Topics in Vitamin D Research, Nova Science Publishers, NY: pp. 67-144.
78. Schwarzel, W. C., Kruggel, W. G., Brodie, H. J. (1973). Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta. Endocrinology 92:866-880.
79. Sheehan, D. J., Hitchcock, C. A., Sibley, C. M. (1999). Current and Emerging Azole Antifungal Agents. Clin. Microbiol. Rev. 12:40-79.
80. Simpson, E. R., Misso, M., Hewit, K. N., Hill, R. A., Boon, W. C., Jones, M. E., Kovacic, A., Zhou, J., Clyne, C. D. (2005). Estrogen - the Good, the Bad, and the Unexpected. Endocrine Reviews 26:322-330.
81. Simpson, E. R., Dowsett, M. (2002). Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog. Horm. Res. 57:317-338.
82. Small, E. J., Baron, A., Bok, R. (1997). Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with "advanced" prostate carcinoma. Cancer 80:1755-1759.
83. Soberman, J. E., Weber, K. T. (2000). Spironolactone in congestive heart failure. Curr. Hypertens Rep. 2:451-456.
84. Sonino, N., Boscaro, M. (1999). Medical therapy for Cushing's disease. Endocrinal Metab. Clin. North Am. 28:211-222.
85. Stearns, M. E., Wang, M., Fudge, K. (1993). Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity. Cancer Res. 53:3073-3077. Erratum in: Cancer Res. 53:5831 (1993).
86. Stowasser, M., Gordon, R. D., Tunny, T. J., Klemm, S. A., Finn, W. L., Krek, A. L. (1992). Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin. Exp. Pharmacol. Physiol. 19:319-322.
87. Trachtenberg, J. (1984). Ketoconazole Therapy in Advanced Prostatic Cancer. J. Urol. 132:61-63.
88. Ulmschneider, S., Muller-Vieira, U., Mitrenga, M., Hartmann, R. W., Oberwinkler-Marchais, S., Klein, C. D., Bureik, M., Bernhardt, R., Antes, I., Lengauer, T. (2005a). Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J. Med. Chem. 48:1796-1805.
89. Ulmschneider, S., Muller-Vieira, U., Klein, C. D., Antes, I., Lengauer, T., Hartmann, R. W. (2005b). Synthesis and evaluation of (pyridylmethylene) tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J. Med. Chem. 48:1563-1575.
90. Van den Bossche, H., Willemsens, G., Bellens, D., Janssen, P. A. (1992a). Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis. Biochem. Pharmacol. 43:739-744.
91. Van den Bossche, H. (1992b). Inhibitors of P450-dependend steroid biosynthesis: from research to medical treatment. J. Steroid. Biochem. Mol. Biol. 43:1003-1021.
92. Van Wauwe J., Van Nyen, G., Coene, M. C., Stoppie, P., Cools, W., Goossens, J. et al. (1992). Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J. Pharmacol. Exper. Ther. 261:773-779.
93. Williams, G., Kerle, D. J., Doble, A., Dunlop, H., Smith, C., Allen, J., Yeo, T., Bloom, S. R. (1986). Objective Responses to Ketoconazole Therapy in Patients with Relapsed Progressive Prostate Cancer. Br J. Urol. 58:45-51.
94. White, J. A., Beckett-Jones, B., Guo, Y-D, Dilworth F. J., Bonasoro, J., Jones, G., Petkovich, M. (1997). cDNA Cloning of Human Retinoic Acid-metabolizing Enzyme (hP450RAI) Identifies a Novel Family of Cytochromes P450 (CYP26). J. Biol. Chem 272:18538-18541.
95. Young, M., Funder, J. W. (2000). Aldosterone and heart. Trends Endocr. Metab. 11:224-226.
96. Zhou, S., Chan, E., Lim, L. Y., Boelsterli, U. A., Li, S. C., Wang, J., Zhang, Q., Xu, A. (2004). Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug. Metab. 5:415-442
97. Zittermann, A. (2003). Vitamin D in preventive medicine: are we ignoring the evidence? Brit. J. Nutr. 89:552-572.